ABSTRACT
INTRODUCTION
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological malignancies as well as the fifth leading cause of cancer-related death among women in the Western countries. A woman's lifetime risk of developing EOC is 1.3%, meaning that one in 78 women will be affected by EOC. Although complete remission following primary treatment is achieved in approximately one half of all patients, the majority of these patients will relapse, and the disease will then become fatal [1, 2] .
Multiple factors influence the prognosisfor EOC patients. Patient overall survival (OS) is affected by the degree of residual disease following surgery, the histological type of the tumor, the type of first-line chemotherapy, the stage of the disease, and the age of the patient at diagnosis [3] . Until recently, cancer studies were mainly focused on the characteristics of the cancer cells themselves. However, it is now known that some features of the tumor stromacan impact patient OS. For example, in a study by Chen et al., patients with stroma-rich ovarian malignancies had www. journals.viamedica.pl/ginekologia_polska a worse prognosis and a higher risk of relapse compared with patients with tumors with poorly developed stroma [4] . Multiple stromal cells, such as cancer-associated fibroblast (CAFs), tumor-infiltrated lymphocytes (TILs), and tumor-associated macrophages (TAMs) secrete growth factors and immunomodulating cytokines that facilitate cancer progression. The development of new blood vessels enables tumor growth and may influence the cancer cell phenotype. The role of tumor stroma is especially important when it comes to cancer invasion and metastasis [5] .Cancer cells can communicate with stromal cells and modify stromal architecture and cell content, creating a more permissive microenvironment to facilitate its own growth [6] . Angiogenesis is one of the most important stromal targets for ovarian cancer therapy. Anti-vascular-endothelial growth factor (VEGF) therapy has a well-established position in the primary treatment of non-optimally debulked ovarian cancer [7] . However, novel therapies targeting stromal cells, such as CAFs and TILs, are also being developed and applied [8] [9] [10] .
Vimentin, a 57 kDa protein, is one of the cytoskeletal proteins belonging to the type III intermediate filament protein family. Vimentin expression in adults is found in a variety of organs and in multiple normal cells [11] . However, vimentin expression increases during cancerogenesis [12] . In addition, vimentin is expressed in numerous cells of the tumor stroma, thus its expression in tumor stroma may reflect the conditions within the tumor microenvironment [13] [14] [15] . Vimentin was traditionally considered a marker of epithelial-to-mesenchymal transition (EMT), the process whereby cells lose their epithelial characteristics and acquirea spindle-shape and the characteristics of mesenchymal cells. EMT is a characteristic phenomenon of cancer cells; associated with tumor infiltrative growth, metastasis and greater resistance to chemotherapy [16] . However, vimentin is not only a cytoskeletal protein responsible for cell architecture and integrity, but also a participant in the regulation of cancer-related signal transduction pathways, such as Raf/14-3-3 and PI3K/AKT, as well asin the extracellular signal-regulated kinase (Erk) pathways responsible for invasiveness, motility, and cell migration. Vimentin is a crucial element of cell migration, invasion, invadopodia development and metastases, and these processes are inhibited by vimentin downregulation [17] . Additionally, current data suggest the important function of vimentin in VEGF-driven angiogenesis, indicating the role of vimentin in tumor stroma rebuilding [18] its exploitation as a clinical target has achieved limited success and novel molecular targets are required.
High expression of vimentin in cancer cells is associated with a poor prognosis for patients with numerous types of neoplasms. Recent studies have also emphasized that elevated stroma vimentin expression correlates with shortened survival rates in colorectal cancer patients [19, 20] .
Although the role of vimentin as a prognostic factor in ovarian cancer has not yet been established, preclinical studies have provided evidence that elevated vimentin expression is associated with platinum sensitivity which suggests a favorable prognosis [21, 22] .
Objectives
The main aim of our research was to evaluate the impact of vimentin expression in ovarian cancer cells and in tumor stromaon the overall survival of patients with malignant ovarian tumors. Furthermore, we tried to determine whether vimentin expression correlates with selected elements of tumor stroma and pathologic characteristics of cancer.
MATERIAL AND METHODS

Patient characteristics
The study material comprised 94 samples of malignant ovarian tumors collected from a group of women treated in the Department of Gynecology and Oncology of the Lukaszczyk Oncological Center, Bydgoszcz, Poland, during the period from 2005 to 2010. The median patient age was 57 (range 25-86). The materials were obtained during primary cytoreductive surgery. The distribution of histopathological findings and FIGO stage of the disease are summarized in Table 1 .The median patient follow-up was 41 months (range 0-160 months). Information on patients who died was retrieved from the 
Immunohistochemistry
The study was performed on a DakoLink48 apparatus, using the EnVision method, with EnVision™ Flex+ kit, Mouse, High pH (Link) (Dako/Agilent, K8002) and ready-to-use murine monoclonal antibody from Dako/Agilent Vimentin (IR630), clone V9. All immunohistochemical studies were performed on 4 μm thick sections taken from cancerous tumors fixed in 4% formalin buffered and embedded in paraffin blocks. Paraffin sections were placed on Knittel Glass adhesive slides and incubated for 2 hours in a chamber thermostat at 60°C. Prior to the automatic performance of the study, tissue sections were subjected to dewaxing followed by thermal epitope detection (HIER) in a PTLink device using EnVision™ FLEX Target Retrieval Solution, High pH (50x) (K8002). Finally, the preparations were dehydrated in a series of alcohols with increasing concentrations and closed in a medium (Consul Mount, Thermo Shandon, USA). The method takes place at room temperature. Each time, a control preparation was added to the series of patient samples. Vimentin immunoreactivity was assessed within the cancer cells and the tumor stroma.The differentiation between stromal and cancer cells infiltrating the tumor stroma was assessed based on cell morphology, and the assessment was performed by an experienced pathologist (W.J.). In the case of cancer cells we used two types of immunoreactivity assessment: 1) evaluation of the staining intensity, and 2) evaluation of the percentage of positive cells. Staining intensity in vimentin cancer cells was stratified into two groups: 1) low expression, including absent (0), minimal (1+) and moderate (2+) expression; and 2) high expression (3+). Vimentin quantitative expression in cancer cells was evaluated using the subjective method of the succeeding approximations assessing the percentage of vimentin positive cells. For our statistical analysis, we distinguished two study groups: 1) comprised of low quantitative vimentin expression (staining found in less than 30% of cells), and 2) comprised of high quantitative vimentin expression (vimentin expression present in more than 30% of cells). Vimentin expression in tumor stroma was assessed by staining intensity. Staining intensity was evaluated by subjective assessment in central and peripheral stroma using a four-degree scale: absent (0), minimal (1+), moderate (2+) and high (3+). The results from the central and peripheral stroma were averaged, and then the expression in the tumor stroma was assessed as either "low" when the results of the calculations were below and including 2, or "high"when above 2. Stromal cellularity was evaluated by assessing the number of tumor stroma cells visible in the microscopic High Power Field (HPF) view. The quantity of tumor stroma cells was evaluated subjectively in the central and peripheral stroma using a three-degree system: 1+, 2+ and 3+, and then the results from the central and peripheral stroma were averaged. Subsequently, the cellularity was assessed as either "low" when the results of calculations were below 1.5, or "high" when above and including 1.5. Immunohistochemistry studies and tumor analyses were performed by an experienced pathologist (W.J.), who was blinded for the results of patients' overall survival. Representative images of vimentin staining are presented in Figure 1 .
Statistical analysis
The data were compared using achi square test. However, if expected cell frequencies were below fiveforthe 2 x 2 contingency table, then the Fisher exact test was performed. Survival analyses were conducted using Kaplan-Meier survival curves. Table 2 summarizes the results of the analysis of vimentin expressionand stromal cellularity.
RESULTS
Vimentin expression and patient OS
High cancer cell vimentin expression intensity was associated with significantly prolonged survival. Patients whose cancer cells had high vimentin expression intensity had a median OS of 100 months (range 0-160) compared with 32 months (range 0-160) for the patients with low vimentin expression intensity in cancer cells (P = 0.007) ( Fig. 2A) .
Patients who suffered from tumors with high quantitative vimentin expression in the cancer cells (up to and including 30% of cells) had a significantly longer median OS (49 months, range 0-160) compared with those patients with low quantitative vimentin expression in the cancer cells (below 30% of cells; 28 months, range 3-134; P = 0.02) (Fig. 2B) .
Patients with low vimentin expression in the tumor stroma hada prolonged OS when compared with patients with high expression. However, thatresult did not achieve a level of statistical significance (117 months, range 0-160 vs 37 months, range 0-148 respectively, P = 0.06; Fig. 1C ). The cellularity of the tumor stroma had no impact on patients' OS.
Relationship between tumor and stroma vimentin expression, and the correlation with stroma cellularity
High tumor cell vimentin expression intensity was associated with significantly higher vimentin stromal expression. There wasno relationship between vimentin quantitative expression in cancer cells and vimentin expression in the tumor stroma (Tab. 3). High vimentin expression in the tumor stroma was correlated with high cellularity of the tumor stroma. Vimentin expression in cancer cells was not associated with tumor stroma cellularity (Tab. 4).
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Vimentin expression and clinicopathologic features of ovarian malignancies
Vimentin expression (in both cancer cells and tumor stroma) did not differ between the histopathological types of ovarian malignancies (Tab. 5). Similarly, there were no differences in vimentin expression with regard to the FIGO stage of the disease and tumor grade (Tab. 6). Non-differentiated (2 tumors), transitional cell carcinomas (3 tumors), borderline tumors (2 tumors) and G1 neoplasms were all excluded from the analysis of clinicopathologic features due to the low number of subjects. Vimentin expression is present in the tumor stroma (yellow arrows). Magnification: x200 and x400 for A) and B) respectively; C) and D) Serous adenocarcinoma of the ovary presenting with minimal vimentin expression in cancer cells (white arrows). Vimentin expression is present in the tumor stroma (yellow arrows). Magnification: x200 and x400 for C) and D) E) and F) Endometrioid adenocarcinoma of the ovary showing moderate vimentin expression in cancer cells (white arrows). Magnification: x200 and x400 for E) and F) respectively; G) and H) Serous adenocarcinoma of the ovary with high vimentin expression in cancer cells (white arrows). Vimentin expression is also found in the tumor stroma (yellow arrows). Magnification: x200 and x400 for G) and H) respectively 
DISCUSSION
Numerous studies have revealed high vimentin expression as a negative prognostic factor in human neoplasms. In the case of colorectal cancer, it was shown that both tumor cell expression and tumor stroma expression were associated with poor patient prognosis [19, 20, 23] . In a meta-analysis by Du et al., vimentin expression indicated a shortened OS and disease-free survival (DFS), lymph node metastases, and a higher TNM stage of colorectal cancer patients [23] . Similarly, a meta-analysis by Yin et al., of 1.598 patients with gastric cancer,has shown vimentin expression to be a prognostic factor of shortened survival [24] . Meta-analysis studies evaluating the expression of vimentin in non-small cell lung cancers have also shown the negative predictive value of vimentin expression. Similarly, vimentin expression was associated with poor prognoses for patients with breast cancer, cervical cancer, lung adenocarcinomas, oral cancers, bladder cancer, and soft tissue leiomyosarcomas [23, 24] . However, not all studies are in full agreement with these reports of the negative prognostic role of vimentin in cancer patients. In a study by Zou et al. involving more than 500 patients with early stage endometrioid cancers, vimentin expression was associated with prolonged survival [25] .
There is sparse data on vimentin tumor expression as a prognostic factor in cases of ovarian cancer. We have identified only one study, by Li et al., which includes analysis of 43 cases of EOC. In their univariate analysis, the authors associate tumor vimentin expression with significantly shortened disease-free survival, whereas in their multivariate analysis the association between vimentin expression and disease-free survival was insignificant. Vimentin expression did not influence EOC patients' OS, in the univariate or multivariate analyses [26] . In our study, we found that both high quantitative vimentin expression and a high intensity of vimentin expression in cancer cells were associated with a better prognosis. This may be explained by the role of vimentin in the regulation of cancer cell platinum-resistance, as this is one of the most important factors influencing patient prognosis [27] . In their study, Huo et al. used two pairs of ovarian cancer cell lines [21] . The authors revealed that the downregulation of vimentin expression increased resistance to cisplatin. Furthermore, their study showed that the upregulation of vimentin expression markedly increased cisplatin sensitivity. The study by Huo et al. is not the only report showing downregulation of vimentin as an indicator of drug resistance in patients with ovarian cancer. Similar results were obtained by Jin et al. where downregulation of vimentin was found among cisplatin-resistant EOC cells [22] . Additionally, Kanakkanthara et al. have shown that low vimentin expression is associated with resistance to microtubule stabilizing agents, such as peloruside A and laulimalide [28] . Taken together, these data suggest that platinum sensitivity related to the expression of vimentin in cancer cells is responsible for the prolonged survival of ovarian cancer patients.
Interestingly, Huo et et al. have revealed that vimentin knockdown cells formed spheroids and they destabilized both anchoring junctions and tight junctions. Additionally, vimentin-downregulated cells acquired stem cell-like characteristics and showed increased expression of stem cell markers [21] . There is a close relationship between cancer stem cell (CSC) phenotype sand cells undergoing EMT, and both are associated with chemoresistance [16] . These findings may indicate that despite acquiring EMT/CSCs features, ovarian cancer cells with higher vimentin expression are characterized by improved sensitivity to platinum-based agents. Thus, an association between vimentin downregulation, EMT, cancer stem-cells phenotypes, and chemoresistance is particularly intriguing and demands further investigation.
We also found that patients with high vimentin expression in the stroma of malignant ovarian tumors had shortened survival compared with patients with low vimentin expression, however, this difference did not reach the level of statistical significance. To the best of our knowledge, our study is the first to report vimentin expression in the stroma of the ovarian neoplasm. We did identify studies showing that a poorer prognosis is related to stromal vimentin expression;but those studies concerned patients with colorectal and prostate cancers [20, 29] . The tumor stroma mainly consists of resident fibroblasts, endothelial cells, pericytes, leukocytes, and extra-cellular matrix. Within the tumor stroma, the CAFs are the most prominent cell type. Vimentin is one of the markers used toidentify CAFs. However, vimentin staining was also noted in normal fibroblasts present in the tumor stroma and in the tumor stroma myofibroblasts (activated fibroblasts) [13] . In addition, vimentin staining was present on the cells of vascular origin, such as the endothelial cells co-labeled with CD31 and pericytes [14] . Further, vimentin may be secreted into extracellular space by activated macrophages [15] . Thus, there are numerous putative sources of tumor stroma vimentin expression. Multiple studies support the role of CAFs in ovarian cancer development and progression; however, the role of normal fibroblasts and myofibroblasts is not fully elucidated [13] .Additionally, current studies indicates that there are various subpopulations of CAFs, and that there are significant differences in their impacts on tumor growth [30] . Although high tumor microvascular density (MVD) is known as apoor prognostic indicator in many human neoplasms, in general, MVD assessed by endothelial staining with an anti-CD31 antibody does not influence ovarian cancer patient prognosis [31] . High vimentin expression may also reflect increased pericyte coverage of tumor blood vessels [14] . On the one hand, tumor vessels with high pericyte coverage build up a more stable vasculature leading to increased tumor growth. On the other hand, high pericyte coverage inhibits tumor hematogenous metastases and is associated with better prognoses for cancer patients [32] . Recent findings suggest that the spread of ovarian cancer by the hematogenous route in patients is far more significant than previously thought [33] .Taken together, these findings show a trend towards a poor prognosis for patients with tumors presenting with high vimentin stromal expression. However, considering the variety of vimentin positive cells within the tumor stroma, further studies are needed for a better identification of these cells. Recently, attention has been paid to interactions between cancer cells and the tumor stroma structure. In this paper, we have evaluated the relationships between vimentin expression in cancer cells with vimentin stromal expression and tumor stroma cellularity. The idea behind this Low vimentin expression intensity in stroma 5 (5%) 9 (10%) P = 0.52 High vimentin expression intensity in stroma 21 (22%) 59 (63%) project was to investigate vimentin as an indicator of stroma remodeling. We have shown that cancer cell vimentin expression strongly correlates with a degree of tumor stroma vimentin expression. Vimentin may be upregulated by a variety of factors, including cancer-related growth factors, such as the transforming growth factor beta (TGF-beta) and the epidermal growth factor (EGF) [34] . Thus, vimentin stromal expression may merely reflect tumor-stroma interactions, whereas cancer cells may influence the stroma compartment. However, vimentin stromal expression may also be explained as a result of specific tumor microenvironmental conditions. For instance, it has been shown that tumor hypoxia through hypoxia-inducible factor-1 (HIF-1) is one of the key elements upregulating the expression of vimentin [35] . In our observations, vimentin expression in tumor stroma was correlated with stroma cellularity. This suggests that vimentin is responsible for, or is just an indicator of, higher stroma infiltration by CAFs and leucocytes. Although we did not observe a correlation between stroma cellularity and the patients' prognoses, EOC with well-developed stroma are characterized by poor prognoses [4] . However, recent studies highlight that the stroma content differs significantly between various cases of EOCs. Additionally, there are various subpopulations of fibroblasts infiltrating tumor stroma. For instance, Givel et al., have shown that the CAF-S1 subset, when present in the stroma of high grade serous ovarian carcinoma has more potent immunosuppressive characteristics when compared with other subsets of CAFs. Additionally, there are various populations of TILs, and while regulatory T-cells indicate poor survival, cytotoxic T-cells indicate better prognoses for cancer patients [9] . These findings suggest that the prognosis of cancer patients is more related to the type of stroma infiltrating cells, and less to their number [30] .
CONCLUSIONS
We conclude that vimentin expression in cancer cells may be used as a potential prognostic factor of the overall survival of patients with ovarian malignancies. Additionally, due to the interactions between vimentin expression in cancer cells with vimentin stromal expressions and stroma cellularity, we suggest vimentin may participate in the formation of tumor stroma. 
